{"id":21505,"date":"2022-06-03T09:55:14","date_gmt":"2022-06-03T07:55:14","guid":{"rendered":"https:\/\/idibell.cat\/?p=21505"},"modified":"2022-06-03T10:50:46","modified_gmt":"2022-06-03T08:50:46","slug":"descobreixen-un-conjunt-de-marcadors-de-mal-pronostic-en-pacients-amb-cancer-de-colon-i-recte","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2022\/06\/descobreixen-un-conjunt-de-marcadors-de-mal-pronostic-en-pacients-amb-cancer-de-colon-i-recte\/","title":{"rendered":"Descobreixen un conjunt de marcadors de mal pron\u00f2stic en pacients amb c\u00e0ncer de c\u00f2lon i recte"},"content":{"rendered":"<p>El principal tractament per al c\u00e0ncer de c\u00f2lon i recte, la <strong>quimioter\u00e0pia<\/strong>, no funciona en tots els pacients. En un grup important, un 30%, es generen resist\u00e8ncies i els tumors provoquen met\u00e0stasi. S\u00f3n pacients amb mal pron\u00f2stic. Ara, un equip d\u2019investigadors ha descobert qu\u00e8 provoca aquesta cadena d\u2019esdeveniments. D\u2019aquesta manera, han pogut determinar un conjunt de marcadors de mal pron\u00f2stic i una potencial diana terap\u00e8utica per aquests malalts. El treball el publica la revista <a href=\"https:\/\/www.nature.com\/articles\/s41467-022-30382-9\"><em>Nature Communications<\/em><\/a>.<\/p>\n<p>En alguns casos i per diverses raons, el tractament amb quimioter\u00e0pia, no \u00e9s suficient per eliminar totes les c\u00e8l\u00b7lules del tumor i una part d\u2019elles sobreviu, passant a un <strong>estat embrionari<\/strong>. A partir d\u2019aqu\u00ed, el tumor pot reapar\u00e8ixer amb m\u00e9s for\u00e7a, sent capa\u00e7 de <strong>resistir al tractament i de generar met\u00e0stasis<\/strong>. Els investigadors han reprodu\u00eft aquest proc\u00e9s en organoides creats a partir de c\u00e8l\u00b7lules de pacients i han pogut comprovar que en les c\u00e8l\u00b7lules que es troben en aquest estat embrionari s\u2019hi expressen un conjunt de gens, en concret, un grup de vuit gens, que s\u00f3n caracter\u00edstics d\u2019aquestes c\u00e8l\u00b7lules tumorals i les fan m\u00e9s agressives. Resultats que han estat confirmats en models ortotopics de c\u00e0ncer colorectal en ratol\u00ed. L\u2019equip de l\u2019IDIBELL i de l\u2019ICO dirigit pel Dr. Alberto Villanueva ha implantat els organoides en ratolins, i ha comprovat que in vivo les c\u00e8l\u00b7lules tumorals continuen expressant els vuit gens que les fan m\u00e9s agressives, i posteriorment han validat el resultats en PDOX\/orthoxenografts derivats de pacients.<\/p>\n<p>&nbsp;<\/p>\n<h3>Possible diana terap\u00e8utica<\/h3>\n<p>Els investigadors consideren que con\u00e8ixer els factors involucrats en el proc\u00e9s de conversi\u00f3 embrion\u00e0ria dels tumors permetr\u00e0 establir el <strong>risc de recaiguda<\/strong> en els pacients amb c\u00e0ncer de c\u00f2lon i recte.<\/p>\n<p>Ara, es treballa per aprofitar aquest descobriment no nom\u00e9s en el pron\u00f2stic dels malalts, tamb\u00e9 per poder <strong>determinar nous tractaments i personalitzar l\u2019abordatge<\/strong> per aquest tipus de pacients de m\u00e9s risc. Identificar el regulador concret de la conversi\u00f3 embrion\u00e0ria d\u2019aquestes c\u00e8l\u00b7lules facilitar\u00e0 aplicar una nova forma de tractar aquests casos, combinant quimioter\u00e0pia i inhibidors concrets dels gens implicats. En aquests moments, ja existeixen alguns f\u00e0rmacs que poden actuar sobre els tumors amb caracter\u00edstiques embrion\u00e0ries.<\/p>\n<p>A m\u00e9s del Dr. Espinosa i de la Dra. Anna Bigas, coordinadora del Grup de recerca en C\u00e8l\u00b7lules Mare i C\u00e0ncer de l\u2019IMIM-Hospital del Mar i directora del CIBERONC, han participat el Dr. Toni Celi\u00e0-Terrassa, coordinador del Grup de recerca en C\u00e8l\u00b7lules mare canceroses i din\u00e0miques de met\u00e0stasis de l\u2019IMIM-Hospital del Mar, i els doctors Antonio Barbachano i Alberto Mu\u00f1oz, de l\u2019Instituto de Investigaciones Biom\u00e9dicas \u2018Alberto Sols\u2019 (IIBM) i investigadors del CIBERONC. Tamb\u00e9 han participat en l\u2019estudi metges i metgesses dels serveis d\u2019Oncologia i d\u2019Anatomia Patol\u00f2gica de l\u2019Hospital del Mar. El treball ha comptat amb el suport de l\u2019Associaci\u00f3 Espanyola contra el C\u00e0ncer (AECC), de la Fundaci\u00f3 hna que dona suport al grup del Dr. Villanueva en la genraci\u00f3 de models PDOX\/orthoxenografts, i dels projectes Nacionals de l\u2019Institut de Salut Carlos III.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><em>L\u2019Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l&#8217;Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l&#8217;Institut Catal\u00e0 de la Salut, l&#8217;Institut Catal\u00e0 d&#8217;Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n<p><em>L\u2019IDIBELL \u00e9s membre del Campus d&#8217;Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L&#8217;any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Es tracta d\u2019un grup de gens que s\u2019expressen a les c\u00e8l\u00b7lules canceroses que sobreviuen al tractament amb quimioter\u00e0pia. La seva activitat genera resist\u00e8ncies al tractament i m\u00e9s capacitat per provocar met\u00e0stasis.<\/p>\n","protected":false},"author":8,"featured_media":21506,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[332,375,447,452,346],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-10 23:10:50","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/21505"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=21505"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/21505\/revisions"}],"predecessor-version":[{"id":21507,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/21505\/revisions\/21507"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/21506"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=21505"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=21505"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=21505"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}